Clincosm LogoSign in Get a demo

Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

Sponsor
Charite University, Berlin, Germany (Other)
Overall Status
Unknown status
CT.gov ID
NCT01220544
Collaborator
University of Leipzig (Other)
30
Enrollment
2
Locations
1
Arm
123
Duration (Months)
15
Patients Per Site
0.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Experimental and clinical data suggest that alloreactive NK cells can reduce the risk of graft-rejection, GvHD and leukemic relapse after HLA-mismatched transplantation. The effectiveness of allogeneic NK cells is a function of HLA-differences between donor and recipient that give rise to NK cell clones which do not express inhibitory receptors matching for the HLA molecules of the recipient. Aim of the study is to evaluate cellular therapy with alloreactive, IL-2 activated NK cells after transplantation of T-cell depleted stem cell grafts from one haplotype mismatched family donors in patients with hematological malignancies.

Condition or Disease Intervention/Treatment Phase
  • Biological: Haploidentical transplantation with donor NK cells
 Phase 1/Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Transplantation of Hematopoetic Stem Cells and Infusion of CD56+CD3- NK Cells From Haploidentical Donors for Patients With Hematological Malignancies
Study Start Date :
Jul 1, 2001
Anticipated Primary Completion Date :
Oct 1, 2010
Anticipated Study Completion Date :
Oct 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: HaploTransplant with NK cells

Haploidentical transplantation of mega-dose CD34+ hematopoetic stem cells with transfer of CD56+CD3-NK cells at day +2

Biological: Haploidentical transplantation with donor NK cells
Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain > 8 x 10e6 CD34+ cells/kg and < 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.

Outcome Measures

Primary Outcome Measures

  1. To evaluate feasibility and safety of alloreactive CD56+/CD3- donor NK cells after one haplotype mismatched transplantation [1 year]

    To evaluate feasibility and safety of cellular immunotherapy with purified alloreactive CD56+/CD3- donor NK cells after one haplotype mismatched hematopoietic stem cell transplantation in patients with high risk hematological malignancies who lack an HLA-identical donor.

Secondary Outcome Measures

  1. transplant related mortality [1 year]

    The investigation of transplant related mortality (incidence of veno occlusive disease; incidence and type of infectious complications).

  2. effectiveness [2 years]

    To evaluate the effectiveness of the therapy (relapse rate; disease free survival; MRD monitoring).

  3. technical aspects of the cell separation procedure [7 days]

    To investigate technical aspects of the cell separation procedure (problems of stem cell mobilization; yield, viability, sterility and purity of the CD34+ and CD56+CD3- cell fraction; log CD3 depletion; in vitro anti-leukemic activity of the CD56+CD3- cell fraction).

  4. stable engraftment of haploidentical stem cell grafts can be achieved after conditioning with total body irradiation, thiotepa, fludarabine and OKT3 and subsequent transfer of megadoses of positively selected CD34+ stem cells and CD56+CD3- NK-cells. [28 days]

    Graft rejection is defined as neutrophils < 0.5 x 10e9/l on day+28 post transplantation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 54 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with AML or ALL in first CR with the following high risk features:

  1. AML with aberration Del (5q) -5, del (7q) -7, t(9;22) or t(6;9), abn 3q, 9q, 11q, 20q, 21q, 17p;

  2. AML with a complex caryotype;

  3. secondary AML after previous chemo- or radiotherapy or MDS;

  4. Ph-positive ALL

  • Patients with AML or ALL after induction failure or in second CR

  • Patients with CML in second chronic or accelerated phase

  • Patients with malignant Lymphoma and the following high risk features:

  1. relapse after autologous transplantation

  2. primary chemotherapy refractory disease

  • All patients must fulfill the following criteria:

  1. lack of a suitable HLA-identical family, unrelated or cord blood donor

  2. no active infection, no severe impairment of cardial, pulmonary, renal and hepatic function

  3. blast count in the marrow < 30%

  4. informed consent

Exclusion Criteria:

  • active infection, no severe impairment of cardial, pulmonary, renal and hepatic function

  • blast count in the marrow > 30%

  • unable or unwilling to sign and/or understand informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Charite Campus Benjamin FRanklin, Medical Clinic III, Department of Hematology/Oncology Berlin Germany 12200
2 Medical Clinic II, Department of Hematology/Oncology, University of Leipzig Leipzig Germany 04103

Sponsors and Collaborators

  • Charite University, Berlin, Germany
  • University of Leipzig

Investigators

  • Principal Investigator: Lutz Uharel, MD, Charite University Medicine
  • Principal Investigator: Dietger Niederwieser, MD, University of Leipzig

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01220544
Other Study ID Numbers:
  • BELEHAPLO-1412001
First Posted:
Oct 14, 2010
Last Update Posted:
Oct 14, 2010
Last Verified:
Oct 1, 2010
Additional relevant MeSH terms:
Neoplasms
Hematologic Neoplasms

Study Results

No Results Posted as of Oct 14, 2010